19 May 2021 07h00 CET– Innovative vaccine manufacturers and biotech companies are at
the forefront of the global effort to develop and manufacture COVID-19 vaccines. This
massive effort is succeeding. After more than 200 clinical trials and nearly 300 partnerships
and collaborations among manufacturers worldwide, production has increased, in just a few
months from zero to 2.2 billion COVID-19 vaccine doses by the end of May with an
astounding estimate of 11 billion doses by the end of 2021 (Airfinity data here). This will be
enough doses to vaccinate the world’s adult population.
Critically, however, COVID-19 vaccines currently are not equally reaching all priority
populations worldwide. Manufacturers, governments, and non-governmental organizations must work
together to take urgent steps to further address this inequity. Immediate action must
focus on stepping up responsible dose sharing and maximizing production without
compromising quality or safety.
To do so, innovative vaccine manufacturers and biotech companies commit to: